Cryoport Reports Third Quarter 2026 Financial Results
Third quarter revenue grew 14% year-over-year to $50.2 million Commercial Cell and Gene Therapy revenue increased 20% year-over-year Supporting a record 788 global clinical trials and 23 commercially approved cell and gene therapies as of September 30, 2026 Raises full-year 2026 revenue...